EVOLVEIMMUNE THERAPEUTICS
EvolveImmune Therapeutics transforms the discovery and development of novel immunotherapies. By leveraging its proprietary in vivo target discovery platform, EvolveImmune is building a pipeline of novel therapeutic candidates against numerous targets that are expressed on multiple immune cell types. The company’s platform will generate first-in-class treatments for unmet needs in oncology and autoimmune diseases.
EVOLVEIMMUNE THERAPEUTICS
Industry:
Biotechnology Health Care
Founded:
2018-01-01
Address:
Westport, Connecticut, United States
Country:
United States
Website Url:
http://www.evolveimmune.com
Total Employee:
1+
Status:
Active
Contact:
+1 203 858 7389
Email Addresses:
[email protected]
Total Funding:
17.55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
D2M Biotherapeutics
D2M Biotherapeutics focuses on the development of novel immunotherapeutics.
Idera Pharmaceuticals
Idera Pharmaceuticals is engaged in the discovery and development of novel synthetic DNA and RNA-based drug candidates.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Raze Therapeutics
Raze Therapeutics, Inc., a biotechnology company, engages in the discovery and development of oncology therapeutics.
Silicon Therapeutics
Silicon Therapeutics is a fully integrated drug design, research, and development company.
Current Employees Featured
Founder
Investors List
Elm Street Ventures
Elm Street Ventures investment in Venture Round - EvolveImmune Therapeutics
Takeda Ventures
Takeda Ventures investment in Venture Round - EvolveImmune Therapeutics
Pfizer
Pfizer investment in Venture Round - EvolveImmune Therapeutics
Solasta Ventures
Solasta Ventures investment in Venture Round - EvolveImmune Therapeutics
Yonjin Venture
Yonjin Venture investment in Venture Round - EvolveImmune Therapeutics
Official Site Inspections
http://www.evolveimmune.com
- Host name: 183.206.174.34.bc.googleusercontent.com
- IP address: 34.174.206.183
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "EvolveImmune Therapeutics"
Leadership - EvolveImmune Therapeutics
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients.See details»
EvolveImmune Therapeutics - Crunchbase Company …
EvolveImmune Therapeutics may be growing as evidenced by their presentation of new preclinical and translational data on their novel CD2 costimulatory T …See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Oct 31, 2024 The discovery partnership will leverage EvolveImmune's T-cell engager platform to develop novel antibody-based therapies for solid and hematologic malignancies. …See details»
Evolveimmune Therapeutics Company Profile | Management and …
Evolveimmune Therapeutics Profile and History EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics …See details»
Evolveimmune Therapeutics - Overview, News & Similar …
View Evolveimmune Therapeutics (www.evolveimmune.com) location in Connecticut, United States , revenue, industry and description. Find related and similar companies as well as …See details»
EvolveImmune Therapeutics - VentureRadar
EvolveImmune leverages our proprietary platform to deliver therapeutic candidates against novel targets across multiple immune cell types. We are rapidly developing first-in-class …See details»
EvolveImmune Therapeutics 2025 Company Profile: Valuation, …
Information on valuation, funding, cap tables, investors, and executives for EvolveImmune Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
EvolveImmune Therapeutics - Contacts, Employees, Board …
EvolveImmune Therapeutics develops a modular biotherapeutics platform specialized in immuno-oncology.See details»
Team - EvolveImmune Therapeutics
At EvolveImmune, we harness our “Immunology First” approach to create first-in-category cancer medicines to transform the lives of patients.See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Oct 31, 2024 About EvolveImmune Therapeutics EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics …See details»
AbbVie and EvolveImmune Therapeutics sign oncology collaboration
Nov 1, 2024 AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop next-generation cancer biotherapeutics. The …See details»
AbbVie and EvolveImmune partner on $65 million cancer therapy …
Oct 31, 2024 The platform is designed to enhance T-cell activation and improve immune responses against cancer. Under the agreement, AbbVie will provide $65 million in upfront …See details»
AbbVie and EvolveImmune Therapeutics partner to innovate new …
Oct 31, 2024 The partnership will harness EvolveImmune’s T-cell engager platform to create novel antibody-based therapies targeting a range of cancers. Together, they aim to advance …See details»
EvolveImmune Therapeutics Presents New Preclinical and …
Nov 11, 2024 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Oct 31, 2024 EvolveImmune's proprietary EVOLVE platform is designed to deliver potent, selective and integrated T-cell co-stimulation to amplify and sustain the tumor killing capacity …See details»
EvolveImmune Therapeutics Presents New Preclinical and …
Nov 12, 2024 EvolveImmune continues to progress its chemistry, manufacturing, and control (CMC) activities for EVOLVE104, with the goal of advancing the program into the clinic in …See details»
AbbVie and EvolveImmune Partner to Advance Next-Gen Cancer ...
Nov 20, 2024 AbbVie and EvolveImmune Therapeutics have entered a strategic collaboration to advance immuno-oncology therapies aimed at overcoming resistance to current cancer …See details»
AbbVie pays $65M for options on EvolveImmune's T-cell engagers
Oct 31, 2024 Days after inking a $1.4 billion buyout, AbbVie has put up the same in biobucks to secure options on multispecific T-cell engagers.See details»
COVID keeps evolving and will find new ways to evade immune
Mar 11, 2025 SARS-CoV-2 has been evolving the ability to evade the immune system about twice as fast as the fastest-evolving flu virus. It averages more than a dozen significant …See details»
AbbVie and EvolveImmune Therapeutics Announce Collaboration …
Nov 7, 2024 EvolveImmune Therapeutics, Inc. is an immunotherapy platform company developing first-in-category, multifunctional biotherapeutics designed to overcome cancer …See details»